Treatment of Choroidal Metastasis from Epidermal Growth Factor Mutant Non-Small Cell Lung Cancer with First-line Osimertinib Therapy.
Treatment of Choroidal Metastasis from Epidermal Growth Factor Mutant Non-Small Cell Lung Cancer with First-line Osimertinib Therapy.
复制标题
DOI：
10.18502/jovr.v17i1.10178
复制
发表时间：
2022-01
影响因子：
2
通讯作者：
Browne AW
中科院分区：
文献类型：
--
作者：
N Vu A;Mehta UV;Israelsen P;Ignatius Ou SH;Browne AW
为了说明通过眼科成像转移病灶的消退，以及与标准胸部成像和奥西替尼治疗的相关性，奥西替尼是一种针对表皮生长因子受体+非小细胞肺癌（EGFR+ NSCLC）的口服化疗药物。一名63岁亚洲男性以左视模糊主诉到眼科就诊。最初的眼科检查显示脉络膜病变，影像学结果突出显示一个棘状肺肿块伴脑和骨转移。选择奥西替尼是因为它的特异性和穿越血脑屏障的能力。在整个治疗过程中重复随访眼科和影像学检查。在开始使用奥西替尼后，眼科和计算机断层成像分别突出了眼部转移性疾病和原发性恶性肿瘤的消退。奥西替尼是EGFR+ NSCLC和相应转移部位的有效一线治疗药物。此外，当发现眼部转移时，眼科成像可用于监测化疗药物的总体反应。
To illustrate the regression of a metastatic lesion through ophthalmic imaging and correlating findings with standard chest imaging and treatment with osimertinib, an oral chemotherapy agent specific to Epidermal Growth Factor Receptor + Non-small Cell Lung Cancer (EGFR+ NSCLC). A 63-year-old Asian male presented to ophthalmology with a complaint of left blurry vision. Initial ophthalmic exam revealed a choroidal lesion and imaging results highlighted a spiculated lung mass with brain and bony metastases. Osimertinib was chosen for its specificity and ability to cross the blood–brain barrier. Follow-up ophthalmic and radiographic imaging were repeated over the course of treatment. After the initiation of osimertinib, ophthalmic and computed tomography imaging highlighted the regression of the ocular metastatic disease and primary malignancy, respectively. Osimertinib is an effective first-line treatment of EGFR+ NSCLC and corresponding metastatic sites. Additionally, ophthalmic imaging can be used to monitor general response to chemotherapy agents when ocular metastasis is identified.